Press Releases

GlobeNewswire, Inc.

Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data...

GlobeNewswire, Inc.

TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027 TX2100 advanced into Phase 1a healthy volunteer clinical trial in February 2026 as a potential treatment for...

GlobeNewswire, Inc.

Company announcement – No. 14 / 2026 Zealand Pharma Announces Financial Results for the First Three Months of 2026 A defining start to 2026, marked by pivotal progress for leading obesity assets, petrelintide and survodutide, and strong momentum...

GlobeNewswire, Inc.

LOWELL, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal second quarter ended April 3,...

GlobeNewswire, Inc.

– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS® in Second Quarter of 2026, Adding...

GlobeNewswire, Inc.

Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment of Mark Soued as Chief Commercial Officer adds...

GlobeNewswire, Inc.

-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue with the FDA toward BLA filing for PM359 in CGD...

GlobeNewswire, Inc.

Strong start to the year with worldwide revenue of $377.3 million in the first quarter 2026 GAAP fully diluted earnings per share of $1.80, compared to $1.02 in the first quarter of 2025 Adjusted fully diluted earnings per share of $1.46, compared...

GlobeNewswire, Inc.

VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- VR Resources Limited (“VR” or the “Company”, TSX.V: VRR, FSE: 5VR; OTCQB: VRRCF) is pleased to announce that the drill program is underway on its New Boston moly-tungsten-copper-silver...

North Carolina Attorney General

FOR IMMEDIATE RELEASE Thursday, May 7, 2026 Contact: comms@ncdoj.gov 919-538-2809 RALEIGH — Attorney General Jeff Jackson joined a bipartisan coalition of 25 attorneys general in urging nine major credit card companies and payment processors...

GlobeNewswire, Inc.

Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk anticipated in H2 2026 Company...

GlobeNewswire, Inc.

-- Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early functional benefit -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026, as well as...

GlobeNewswire, Inc.

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Bank of America Securities 2026 Global...

North Carolina Attorney General

FOR IMMEDIATE RELEASE Thursday, May 7, 2026 Contact: comms@ncdoj.gov 919-538-2809 RALEIGH — Attorney General Jeff Jackson joined a bipartisan coalition of 25 attorneys general in urging nine major credit card companies and payment processors...

EIN Presswire

Management consulting is evolving from a luxury into a vital survival tool amid rapid disruption and regulatory change.

GlobeNewswire, Inc.

FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic...

GlobeNewswire, Inc.

Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RAP-219 Phase 2 trial in bipolar mania topline...

GlobeNewswire, Inc.

Hosted virtual Analyst Day showcasing lead program KRRO-121’s potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE); regulatory filing for...

GlobeNewswire, Inc.

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025 Akebia hosted virtual R&D Day...

GlobeNewswire, Inc.

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- The Boston Beer Company, Inc. (NYSE: SAM), today reported financial results for the first quarter ended March 28, 2026. Key results were: First Quarter 2026 Summary: Depletions decreased 4% and shipments...